NEJM
https://pubmed.ncbi.nlm.nih.gov/?myncbishare=dukemlib&dr=abstract&otool=dukemlib&term=33789013
Bottom line- patients with dm and established heart disease should take the medication with proven cardiovascular benefits such as a GLP-1 receptor agonist or an SGLT2 inhibitor. In pts with dm and heart failure with reduced EF or with chronic CKD, SGLT2 inhibitors with proven benefit should be considered. If weight loss is a consideration the GLP-1 receptor agonist class is more helpful.